Business Standard

Lupin launches Mesalamine Extended-Release Capsules 0.375 g in US market

Image

Capital Market
Lupin announced the launch of authorized generic version of Bausch Health's Apriso (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.

Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.

Mesalamine Extended-Release Capsules 0.375 g, RLD: Apriso had an annual sales of approximately USD 290 million in the U.S. (IQVIA MAT March 2020).

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 19 2020 | 1:41 PM IST

Explore News